Skip to content

Assessment of pathological response after neoadjuvant therapy for esophageal cancer based on deep learning

Assessment of pathological response after neoadjuvant therapy for esophageal cancer based on deep learning

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600123916
Enrollment
Unknown
Registered
2026-04-30
Start date
2026-05-01
Completion date
Unknown
Last updated
2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal squamous cell carcinoma

Interventions

Observation group:None

Sponsors

?Zhejiang Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Histopathologically confirmed esophageal squamous cell carcinoma (ESCC); 2.Received preoperative anti-tumor therapy, including chemotherapy, radiotherapy, chemoradiotherapy, chemotherapy combined with immunotherapy, or chemoradiotherapy combined with immunotherapy; 3.Underwent curative esophagectomy with R0 resection; 4.Age >=18 years; 5.Complete imaging and pathological data available: whole-slide digital pathology images of resected specimens can be obtained.

Exclusion criteria

Exclusion criteria: 1.Histopathological type is non-squamous cell carcinoma or mixed pathological type; 2.Only exploratory surgery or palliative resection was performed, without achieving radical resection; 3.Concurrent or previous history of other active malignant tumors; 4.Previous history of anti-tumor therapy; 5.Missing or poor-quality data: pathological slides cannot be obtained or image resolution is insufficient for analysis.

Design outcomes

Primary

MeasureTime frame
Diagnostic accuracy of pathological response assessment model;

Countries

China

Contacts

Public ContactXu Liwei

?Zhejiang Cancer Hospital

xulw@zjcc.org.cn+86 158 5718 1980

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 7, 2026